287 related articles for article (PubMed ID: 17292563)
1. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
2. [Serum anti-p53 antibodies in gastric cancer patients].
Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
[TBL] [Abstract][Full Text] [Related]
3. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
4. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma.
Maehara Y; Kakeji Y; Watanabe A; Baba H; Kusumoto H; Kohnoe S; Sugimachi K
Cancer; 1999 Jan; 85(2):302-8. PubMed ID: 10023696
[TBL] [Abstract][Full Text] [Related]
6. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
Shimada H; Ochiai T; Nomura F;
Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
[TBL] [Abstract][Full Text] [Related]
7. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
[TBL] [Abstract][Full Text] [Related]
8. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.
Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR
Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393
[TBL] [Abstract][Full Text] [Related]
9. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
10. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade.
Wu CW; Lin YY; Chen GD; Chi CW; Carbone DP; Chen JY
Br J Cancer; 1999 May; 80(3-4):483-8. PubMed ID: 10408857
[TBL] [Abstract][Full Text] [Related]
11. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
13. Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies.
Bielicki D; Karbowniczek M; Sulzyc-Bielicka V; Kładny J; Boer C; Marlicz K; Domagała W
Pol J Pathol; 1999; 50(2):77-81. PubMed ID: 10481530
[TBL] [Abstract][Full Text] [Related]
14. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.
Creaney J; McLaren BM; Stevenson S; Musk AW; de Klerk N; Robinson BW; Lake RA
Br J Cancer; 2001 Jan; 84(1):52-6. PubMed ID: 11139313
[TBL] [Abstract][Full Text] [Related]
15. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma.
Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Genazzani AR
Anticancer Res; 1998; 18(5B):3763-5. PubMed ID: 9854491
[TBL] [Abstract][Full Text] [Related]
16. Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers.
Wang JY; Hsieh JS; Chen CC; Tzou WS; Cheng TL; Chen FM; Huang TJ; Huang YS; Huang SY; Yang T; Lin SR
J Surg Res; 2004 Aug; 120(2):242-8. PubMed ID: 15234219
[TBL] [Abstract][Full Text] [Related]
17. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
18. [Clinical importance of serum anti-p53 antibodies as tumor markers].
Sakai H; Okamoto E
Rinsho Byori; 2002 Oct; 50(10):970-5. PubMed ID: 12451677
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]